Presentation is loading. Please wait.

Presentation is loading. Please wait.

Antimicrobial Prescribing in the Management of COPD

Similar presentations

Presentation on theme: "Antimicrobial Prescribing in the Management of COPD"— Presentation transcript:

1 Antimicrobial Prescribing in the Management of COPD
Dr Teck Wee Boo Consultant Microbiologist, GUH Senior Lecturer, Bacteriology, NUI Galway

2 Exacerbation of COPD Acute event
Worsening of patient’s respiratory symptoms beyond normal day-to-day variations Leading to a change in medication - GOLD guidelines 2011

3 Impact of COPD exacerbations
Quality of life – negative impact Accelerate rate of decline in lung function Significant mortality, esp in hospitalised patients Socioeconomic costs

4 Clinical diagnosis of exacerbation
Acute change of symptoms beyond baseline levels: Change in purulence of sputum Increase in sputum volume Increase in dyspnoea

5 Causes of exacerbation of COPD
Infective causes (~80-85%) Bacterial causes Viral causes Non-infective causes (~15-20%?) Air pollution Other factors

6 Infective causes Bacterial (50%): Haemophilus influenzae
Streptococcus pneumoniae Moraxella catarrhalis Pseudomonas aeruginosa (advanced disease) Chlamydophila pneumoniae Mycoplasma pneumoniae ?S. aureus; ?E. coli; ?Pneumocystis

7 Infective causes Viral (20-30%): Mixed (viral-bacterial): Rhinovirus
Influenza and Parainfluenza viruses Respiratory syncytial virus Others Mixed (viral-bacterial): Potential synergistic activity


9 Pathophysiology Baseline bacterial colonisation ↓
Acute trigger (eg. new bacterial/viral strain) Acute-on-chronic inflammation (epithelial adhesion, chemokines, neutrophils) Increase in respiratory symptoms (+/- systemic) Development of immune response

10 Antimicrobial therapy in COPD exacerbation
Treatment of bacterial infection in exacerbation of COPD can reduce mortality and treatment failure Not always easy to distinguish between bacterial vs viral causes Severity of symptoms Purulent sputum: increased likelihood of bacterial aetiology Anthonisen et al (1987); Stockley et al (2000)

11 Antimicrobial therapy in COPD exacerbation
Benefit seen in moderate or severe exacerbations Anthonisen et al.: greatest benefit from antibiotic Rx in patients with presence of all 3 symptoms (increased dyspnoea, sputum purulence & volume) Berry et al.; Allegra et al.: benefit of Rx seen in moderate & severe cases

12 Recommendations for antimicrobial therapy
NICE (National Institute for Clinical Excellence, NHS) guideline (2004): antimicrobial Rx for COPD exacerbations associated with history of more purulent sputum GOLD (Global initiative for chronic Obstructive Lung Disease) (2011): Rx for patients with all 3 symptoms, or 2 symptoms one of which is purulent sputum

13 Choice of antimicrobial agents
Most guidelines recommend: Aminopenicillin (eg. amoxicillin or amoxicillin-clavulanate) Or Macrolide (eg. clarithromycin) Tetracycline (eg. doxycycline)

14 PO dosages Amoxicillin 500mg – 1g TDS
Amoxicillin-clavulanate 625mg TDS Clarithromycin 500mg BD

15 Choice of antimicrobial agents
Need to be guided by local susceptibility patterns as well Other considerations: severity of illness, risk factors: age ≥65; comorbidities like cardiac disease or diabetes; advanced disease; frequency of exacerbations, recent antibiotics, etc.


17 Antimicrobial susceptibility
Respiratory isolates 2008, 2009 Streptococcus pneumoniae: Penicillin (oral): 10% high-level resistance Erythromycin: 25-31% resistance Tetracycline: 18-23% resistance

18 When to send sputum for culture
Severe cases of exacerbation Hospitalised patients; mechanical ventilation Non-response to standard treatment Frequent Rx courses Concern re: possibility of P. aeruginosa

19 Duration of treatment Generally: 5-10 days
Meta-analysis (El Moussaoui et al., 2008): 5-day course just as efficacious as 7-10 day course for mild-to-moderate cases Any risk factors for poorer outcome? Individual patient’s clinical response

20 Preventative measures
Influenza vaccination Reduce mortality & severity of illness Reduce late exacerbations? Pneumococcal vaccination No direct evidence of efficacy in reducing pneumococcal exacerbations But may benefit from reducing incidence of pneumococcal pneumonia

21 Summary Significant proportion of exacerbations of COPD are due to bacterial pathogens Treatment of bacterial exacerbation can be beneficial to patient Sputum purulence should be used to guide indication for antimicrobial therapy Average Rx duration 5-10 days

22 Thank you!

Download ppt "Antimicrobial Prescribing in the Management of COPD"

Similar presentations

Ads by Google